Recommendations for prevention and treatment of glucocorticoid-induced osteoporosis in patients with rheumatic disorders;Doporučení prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatický m onemocněním (Společné stanovisko Č eské revmatologické společnosti a Společnosti pro metabolická onemocnění skeletu)

Ceska Revmatologie

Volumn 12, Issue 4, 2004, Pages 163-174

  Ruzickova O ^c   Bayer, M ^a   Pavelka, K ^c   Palicka V ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

Bisphosphonates; Bone mineral density; Calcitonin; Calcium; Glucocorticoid induced osteoporosis; Hormone replacement therapy; Parathormon; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALFACALCIDOL; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; HORMONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; THYROTROPIN; VITAMIN D;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; CHRONIC INFLAMMATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE SUBSTITUTION; HUMAN; INFLAMMATORY DISEASE; LOW DRUG DOSE; OSTEOLYSIS; PATHOPHYSIOLOGY; PREVALENCE; REFERENCE VALUE; RHEUMATIC DISEASE; RISK FACTOR; STEROID THERAPY; VERTEBRA BODY; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 11244251878     PISSN: 12107905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Adachi JD, Bensen WG, Hodsman AB. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 1993; 22: 375-384.
2. Olbricht T, Benker G. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases. J Intern Med 1993; 234: 237-244.
3. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993; 20: 1666-9.
4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1994; 54: 49-52.
5. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994; 20: 630-651.
6. Sambrook PN, Jones G. Corticosteroid osteoporosis. Br J Rheumatol 1995; 34: 8-12.
7. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.
8. Lane NE, Mroczkowski PJ, Hochberg MC. Prevention and management of glucocorticoid-induced osteoporosis. Bull Rheum Dis 1995; 44: 1-4.
9. Rovenský J, et al. Revmatologické projevy u pacientů s endokrinními chorobami, In: Pavelka K, Rovenský J, et al. Klinická revmatologie. Praha: Galén, 2003, 533-546s.
10. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383-9.
11. Saag K, Koehnke R, Caldwell J, et al. Low dose long-term corticosteroid therapy in RA: an analysis of serious adverse events. Am J Med 1994; 96: 115-23.
12. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791-801.
13. Health Care Finance Administration. Bone Mass Measurement Act. 63 Federal Register 34321 (1998, June 24).
14. Levis S, Altman R. Bone densitometry: clinical considerations. Arthritis Rheum 1998; 41: 577-87.
15. Rosa J, Kostní denzitometrie, In: Pavelka K, Rovenský J, et al. Klinická revmatologie. Praha: Galén, 2003, 153-164 s.
16. Sambrook PN, Diamond T, Ferris L, et al. Corticosteroid induced osteoporosis - guidelines for the treatment. Australian Family Physician 2001; 30: (8).
17. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14: 1061-6.
18. Canalis E. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes 2000; 7: 320-4.
19. Weinstein RS. The pathogenesis of glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 2000; 18 (Suppl 21): S35-40.
20. Pavelka K, et al. Revmatoidní artritida, In: Pavelka K, Rovenský J, et al. Klinická revmatologie. Praha: Galén, 2003; 181-246 s.
21. American College of Rheumatology Ad Hoc Commitee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update. Arthritis Rheum 2001; 44: 1496-1503.
22. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl).
23. Saag KG, Emkey R, Schnnitzer TJ, et al. Alendronate for the treatment and prevention of glulcocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9.
24. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo controlled trial. Ann Intern Med 1996; 125: 961-86.
25. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 1006-20.
26. Sambrook PN, Birmingham J, Kelly P, Kempler S, Pocock NA, Eisman JA. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747-52.
27. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol ind corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9: 75-81.
28. Amin S, La Valley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999; 42: 1740-51.
29. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis Cochrane review, In: The Cochrane Library. Issue 2. Oxford(UK): Update Software; 2000.
30. Buckley LM, Hillner B. A cost-effectiveness analysis of calcium and vitamin D vs alendronate in the prevention of corticosteroid-induced osteoporos (Abstract). Arthritis Rheum 1997; 40 (Suppl 9): S136.
31. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-7.
32. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309-18.
33. Rodan GA, Fleisch HA. Bisphosphonates: mechanism of action. J Clin Invest 1996; 97: 2692-696.
34. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-505.
35. Lane NE, Roe B, Genant HK, Arnaud C. Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomized controlled trial. J Clin Invest 1998; 102: 1627-33.
36. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Intitiative Randomized Controlled Trial. JAMA 2002; 132: 689-96.
37. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-7.
38. Petak SM, Baskin HJ, Bergman DA, Dickey RA, Nankin HA. AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients. Accessed December 20, 2000. URL: (http://www.aace.com/clin/guides/hypogonadism.html).
39. Drinkwater BL, Nilson K, Ott S, Chesnut CH. Bone mineral density after resumption of menses in amenorrheic women. JAMA 1986; 256: 380-2.
40. Drinkwater BL, Nilson K, Chesnut CH, Brenner WJ, Shainholtz S, Southworth WB. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 1984; 311: 277-281.
41. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-77.
42. Ettinger B, Black DM, Mitlak BH, et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45.
43. Repchinsky C (editor). Compendium of pharmaceuticals and specialties. 36. Ottawa: Canadian Pharmacists Association, 2001: 236-7.
44. Repchinsky C (editor). Compendium of pharmaceuticals and specialties. 36. Ottawa: Canadian Pharmacists Association, 2001: 244-5.
45. Repchinsky C (editor). Compendium of pharmaceuticals and specialties. 36. Ottawa: Canadian Pharmacists Association, 2001: 924-6.
46. Luengo M, Picado C, Del Rio L, Guanabens A, Montserrat JM, Setoain J. Treatment of steroid-induced osteopenie with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis 1990; 142: 104-7.
47. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997; 36: 255-9.
48. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgie rheumatica. Calcif Tissu Int 1996; 58: 73-80.
49. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35-9.
50. Kotaniemi A, Piirainen H, Paimela L, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 1996; 23: 1875-9.
51. Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma? A two year follow up study. Thorax 1994; 49: 1099-102.
52. Grotz WH, Rump LC, Niessen A, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998; 66: 1004-8.
53. Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis Cochrane review, In: The Cochrane Library. Issue 2. Oxford(UK): Update Software; 2000.
54. Lems WF, Jacobs WG, Bijlsma JW, et al. Effect of sodium fluoride on the prevention of corcticosteroid-induced osteoporosis. Osteoporos Int 1997; 7: 575-82.
55. Lems WF, Jacobs WG, Bijlsma JW, et al. Is the addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid-induced osteoporosis? Ann Rheum Dis 1997; 56: 357-63.
56. Lane NE, Sanchez S, Modin G, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15: 944-51.
57. Adami S, Fossaluzza V, Rossini M, et al. The prevention of corticosteroid-induced osteoporosis with nandroline deconoate. Bone Miner 1991; 15: 72-81.
58. Greco EO, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990; 46: 294-9.